Comprehensive multi-gene NGS panels analyzing 10-500+ genes for hereditary cancers, cardiac disorders, neurological conditions, metabolic diseases, and carrier screening.

Details:

Next-Generation Sequencing (NGS) has revolutionized genetic testing by enabling simultaneous analysis of multiple genes associated with hereditary diseases. NGS panels can examine anywhere from 10 to 500+ genes in a single test, providing comprehensive genetic information for diagnosis, risk assessment, and family planning.

What NGS Technology Offers

• Multi-Gene Panel Testing: Analyze 10-500+ genes related to specific conditions
• Whole Exome Sequencing (WES): Examine all approximately 20,000 proteincoding genes
• Targeted Disease Panels: Focus on genes associated with specific inherited conditions
• Comprehensive Analysis: Detect mutations missed by single-gene testing
• Cost-Effective: Test multiple genes simultaneously at lower cost than sequential tests

Types of Hereditary Disease Panels

Cancer Genetics:

• Hereditary Breast and Ovarian Cancer: BRCA1, BRCA2, PALB2, ATM, CHEK2, and 20+ other genes
• Lynch Syndrome: MLH1, MSH2, MSH6, PMS2, EPCAM genes (colorectal cancer risk)
• Hereditary Cancer Panel: 50-80+ genes covering multiple cancer types
• Li-Fraumeni Syndrome: TP53 gene (multiple cancer predisposition)

Cardiovascular Genetics:

• Cardiomyopathy Panel: Genes causing hypertrophic, dilated, or arrhythmogenic cardiomyopathy
• Arrhythmia Panel: Long QT syndrome, Brugada syndrome, CPVT genes
• Familial Hypercholesterolemia: LDLR, APOB, PCSK9 genes
• Aortic Disease Panel: Marfan syndrome, Loeys-Dietz syndrome genes

Neurological Disorders:

• Epilepsy Panel: 100+ genes causing genetic epilepsies
• Neurodevelopmental Disorders: Autism, intellectual disability genes
• Neurodegenerative Disease: Early-onset Alzheimer’s, Parkinson’s, ALS genes
• Movement Disorders: Dystonia, ataxia, hereditary spastic paraplegia genes

Metabolic Disorders:

• Comprehensive Metabolic Panel: 400+ genes for inborn errors of metabolism
• Mitochondrial Disease Panel: Nuclear and mitochondrial genes
• Glycogen Storage Diseases: Including GBE1 gene and related disorders

Reproductive/Carrier Screening:

• Expanded Carrier Screening: 100-500+ recessive disease genes
• Cystic Fibrosis: CFTR gene comprehensive analysis
• Fragile X Syndrome: FMR1 gene testing
• Spinal Muscular Atrophy: SMN1 gene
• Sickle Cell and Thalassemia: Hemoglobin gene variants

Variant Classification

Variants are classified according to ACMG/AMP guidelines:

• Pathogenic (P): Known disease-causing variant
• Likely Pathogenic (LP): Very likely disease-causing (greater than 90% certainty)
• Variant of Uncertain Significance (VUS): Unknown clinical significance
• Likely Benign (LB): Probably not disease-causing
• Benign (B): Definitively not disease-causing

What Your Report Includes

• Clinical Summary: Overall test interpretation and recommendations
• Result Summary Table: Variants categorized by significance
• Detailed Variant Information: Specific gene and DNA change, protein effect, inheritance pattern, associated diseases, population frequency, supporting evidence
• Clinical Recommendations: Follow-up testing, screening, or management suggestions
• Family Implications: Relatives who may benefit from testing
• Genetic Counseling Guidance: Interpretation and family planning information

Clinical Applications

• Diagnostic Testing: Identify cause of symptoms or disease
• Predictive Testing: Assess risk before symptoms appear
• Carrier Screening: Family planning decisions
• Cascade Testing: Test family members after positive result
• Prenatal/Preimplantation: Test fetus or embryos
• Cancer Risk Assessment: Guide screening and prevention

Benefits of NGS Panel Testing

• Comprehensive analysis of all relevant genes at once
• Higher diagnostic yield than single-gene testing
• Identifies unexpected genetic causes
• Cost-effective compared to sequential testing
• Faster results than traditional methods
• Guides personalized medical management
• Informs family members’ risks

Important Considerations

• Genetic Counseling Strongly Recommended before and after testing
• Variants of Uncertain Significance (VUS) may require follow-up or reclassification over time
• Incidental Findings: May discover unrelated health risks
• Family Implications: Positive results affect blood relatives
• Psychological Impact: Results may cause anxiety
• Insurance Considerations: GINA protections for health/employment, but not life insurance
• Evolving Science: Interpretation may change as knowledge advances

Who Should Consider NGS Testing

• Personal or family history of genetic condition
• Multiple family members with same disease
• Early-onset disease (e.g., cancer before age 50)
• Unexplained symptoms suggestive of genetic disorder
• Planning pregnancy (carrier screening)
• Failed to get diagnosis with prior testing
• Multiple affected organ systems

Sample Requirements

• Blood sample (preferred) or saliva
• Results typically available in 2-4 weeks
• One-time testing (genes do not change)